Squarepoint’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.49M | Buy |
299,449
+121,154
| +68% | +$1.25M | ﹤0.01% | 2028 |
|
|
2025
Q4 | $2.2M | Buy |
178,295
+5,498
| +3% | +$58.9K | ﹤0.01% | 1993 |
|
|
2025
Q3 | $1.52M | Buy |
172,797
+148,357
| +607% | +$1.15M | ﹤0.01% | 2319 |
|
|
2025
Q2 | $156K | Sell |
24,440
-203,496
| -89% | -$1.16M | ﹤0.01% | 4053 |
|
|
2025
Q1 | $1.11M | Buy |
227,936
+180,718
| +383% | +$1.5M | ﹤0.01% | 2572 |
|
|
2024
Q4 | $451K | Sell |
47,218
-163,227
| -78% | -$1.5M | ﹤0.01% | 3808 |
|
|
2024
Q3 | $1.76M | Sell |
210,445
-20,569
| -9% | -$187K | ﹤0.01% | 2157 |
|
|
2024
Q2 | $1.58M | Buy |
+231,014
| New | +$994K | ﹤0.01% | 2224 |
|
|
2024
Q1 | – | Sell |
-79,181
| Closed | -$190K | – | 4158 |
|
|
2023
Q4 | $190K | Sell |
79,181
-508,220
| -87% | -$1.19M | ﹤0.01% | 3614 |
|
|
2023
Q3 | $2M | Buy |
587,401
+538,599
| +1,104% | +$2.99M | ﹤0.01% | 1825 |
|
|
2023
Q2 | $359K | Buy |
48,802
+22,071
| +83% | +$205K | ﹤0.01% | 2848 |
|
|
2023
Q1 | $277K | Buy |
26,731
+16,322
| +157% | +$197K | ﹤0.01% | 2624 |
|
|
2022
Q4 | $123K | Sell |
10,409
-3,771
| -27% | -$58.4K | ﹤0.01% | 2933 |
|
|
2022
Q3 | $298K | Buy |
+14,180
| New | +$395K | ﹤0.01% | 2489 |
|
|
2022
Q1 | – | Sell |
-6,661
| Closed | -$290K | – | 3002 |
|
|
2021
Q4 | $290K | Buy |
6,661
+3
| +0% | +$136 | ﹤0.01% | 2467 |
|
|
2021
Q3 | $333K | Buy |
+6,658
| New | +$403K | ﹤0.01% | 2200 |
|
|
2021
Q2 | – | Sell |
-21,958
| Closed | -$2.04M | – | 3345 |
|
|
2021
Q1 | $2.04M | Buy |
+21,958
| New | +$2.25M | 0.01% | 1057 |
|
|
2020
Q4 | – | Sell |
-15,785
| Closed | -$1.63M | – | 2992 |
|
|
2020
Q3 | $1.63M | Sell |
15,785
-28,355
| -64% | -$3.06M | 0.02% | 742 |
|
|
2020
Q2 | $3.49M | Buy |
44,140
+12,177
| +38% | +$907K | 0.06% | 453 |
|
|
2020
Q1 | $1.85M | Buy |
31,963
+21,418
| +203% | +$1.23M | 0.05% | 465 |
|
|
2019
Q4 | $569K | Buy |
10,545
+3,974
| +60% | +$216K | ﹤0.01% | 1691 |
|
|
2019
Q3 | $344K | Sell |
6,571
-33,741
| -84% | -$1.57M | ﹤0.01% | 1826 |
|
|
2019
Q2 | $1.95M | Buy |
+40,312
| New | +$1.93M | 0.02% | 866 |
|
|
2019
Q1 | – | Sell |
-5,762
| Closed | -$342K | – | 2210 |
|
|
2018
Q4 | $342K | Sell |
5,762
-3,727
| -39% | -$240K | ﹤0.01% | 1440 |
|
|
2018
Q3 | $625K | Buy |
+9,489
| New | +$554K | 0.01% | 1207 |
|
|
2018
Q1 | – | Sell |
-29,928
| Closed | -$1.39M | – | 1790 |
|
|
2017
Q4 | $1.39M | Buy |
29,928
+4,558
| +18% | +$192K | 0.02% | 683 |
|
|
2017
Q3 | $1.03M | Buy |
+25,370
| New | +$918K | 0.02% | 717 |
|
|
2017
Q1 | – | Sell |
-11,967
| Closed | -$393K | – | 1604 |
|
|
2016
Q4 | $393K | Buy |
+11,967
| New | +$359K | 0.02% | 963 |
|
|
2016
Q3 | – | Sell |
-57,959
| Closed | -$1.63M | – | 1070 |
|
|
2016
Q2 | $1.63M | Buy |
+57,959
| New | +$2.27M | 0.1% | 235 |
|
|
2016
Q1 | – | Sell |
-13,515
| Closed | -$541K | – | 1225 |
|
|
2015
Q4 | $541K | Buy |
+13,515
| New | +$471K | 0.06% | 497 |
|
Other funds holding EBS
VCM
PCM
VPM
Squarepoint's EBS Position: Q1 2026 in Review
Squarepoint increased its Emergent Biosolutions (EBS) stake by 68% in Q1 2026, buying an estimated $1.25M and bringing the position to 299,449 shares worth $2.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2028.
Squarepoint first reported a position in EBS in Q4 2015 and has held it in 30 quarters since. The position peaked at $3.49M in Q2 2020. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.
- Squarepoint held 299,449 shares of Emergent Biosolutions worth $2.49M as of Q1 2026.
- Squarepoint bought 121,154 Emergent Biosolutions shares in Q1 2026, an estimated $1.25M.
- Emergent Biosolutions made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2028 holding.
- Squarepoint first reported a position in Emergent Biosolutions in Q4 2015 and has held it in 30 quarters since.
- Squarepoint's Emergent Biosolutions position peaked at $3.49M in Q2 2020.
- 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.